Tong Ren Tang Technologies Co Ltd Class H (HK:1666)
:1666
Want to see HK:1666 full AI Analyst Report?
Top Page
Tong Ren Tang Technologies Co
(1666)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$4.00
â–¼(-10.91% Downside)
Action:ReiteratedDate:04/30/26
The score is driven primarily by mixed fundamentals: a healthy, improving balance sheet and a strong 2025 cash-flow rebound are offset by a clear 2025 slowdown in revenue and profitability and prior-year cash-flow volatility. Technicals are notably weak with price below key moving averages and negative MACD, while valuation helps support the overall score due to a moderate P/E and attractive dividend yield.
Positive Factors
Strong TCM brand
Tong Ren Tang's recognized TCM brand and heritage provide durable competitive advantage in trust-driven healthcare products. Brand equity supports premium positioning, channel access and repeat customer demand, underpinning sustainable revenue sources and resilience versus newer entrants.
Negative Factors
Revenue decline
A meaningful revenue contraction (-9.1% in 2025) indicates weakening end-market demand or loss of momentum. Sustained top-line decline compresses operating leverage, limits reinvestment capacity and raises strategic urgency to restore growth over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TCM brand
Tong Ren Tang's recognized TCM brand and heritage provide durable competitive advantage in trust-driven healthcare products. Brand equity supports premium positioning, channel access and repeat customer demand, underpinning sustainable revenue sources and resilience versus newer entrants.
Read all positive factors
Tong Ren Tang Technologies Co (1666) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.93B
Dividend Yield4.47%
Average Volume (3M)1.05M
Price to Earnings (P/E)13.1
Beta (1Y)0.76
Revenue Growth-10.79%
EPS Growth-24.52%
CountryHK
Employees3,991
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.05
Shares Outstanding628,704,000
10 Day Avg. Volume1,287,300
30 Day Avg. Volume1,053,233
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.69
Price to Sales (P/S)0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.50Price Target Upside22.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.35
Revenue Forecast (FY)HK$7.00B
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Company Description
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and f...
How the Company Makes Money
null...
Tong Ren Tang Technologies Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.32B | 7.26B | 6.77B | 5.99B | 5.40B |
| Gross Profit | 2.40B | 2.88B | 2.85B | 2.59B | 2.29B |
| EBITDA | 1.11B | 1.17B | 1.30B | 1.39B | 1.26B |
| Net Income | 386.02M | 521.79M | 590.19M | 582.89M | 507.25M |
Balance Sheet | |||||
| Total Assets | 13.72B | 14.41B | 13.51B | 12.48B | 11.59B |
| Cash, Cash Equivalents and Short-Term Investments | 4.84B | 4.38B | 4.24B | 4.18B | 3.89B |
| Total Debt | 2.17B | 2.43B | 1.63B | 1.59B | 1.64B |
| Total Liabilities | 3.34B | 4.24B | 3.86B | 3.47B | 3.44B |
| Stockholders Equity | 7.34B | 7.21B | 6.89B | 6.48B | 5.98B |
Cash Flow | |||||
| Free Cash Flow | 1.45B | -158.56M | 450.78M | 565.85M | 877.01M |
| Operating Cash Flow | 1.56B | 15.61M | 554.17M | 723.77M | 1.03B |
| Investing Cash Flow | 50.30M | 1.05B | -1.07B | 43.01M | -197.36M |
| Financing Cash Flow | -1.01B | 288.35M | -497.76M | -499.45M | -474.67M |
Tong Ren Tang Technologies Co Technical Analysis
Negative
4.49
Price Trends
4.18
Negative
4.36
Negative
4.67
Negative
Market Momentum
-0.08
Negative
42.29
Neutral
49.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1666, the sentiment is Negative. The current price of 4.49 is above the 20-day moving average (MA) of 3.99, above the 50-day MA of 4.18, and below the 200-day MA of 4.67, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 42.29 is Neutral, neither overbought nor oversold. The STOCH value of 49.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1666.
Tong Ren Tang Technologies Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$96.17B | 22.87 | 11.96% | 2.70% | -10.34% | -8.11% | |
67 Neutral | HK$779.10M | 3.58 | 12.80% | 7.52% | -9.66% | 16.17% | |
60 Neutral | HK$4.93B | 13.14 | 5.98% | 4.47% | -10.79% | -24.52% | |
59 Neutral | HK$6.18B | 10.91 | 12.72% | 4.04% | -6.10% | -20.60% | |
54 Neutral | HK$8.56B | -28.37 | -1.64% | 3.66% | -10.68% | -737.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$356.60M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% |
* Healthcare Sector Average
HK:1666
Tong Ren Tang Technologies Co
3.85
-0.71
-15.50%
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
7.38
-0.72
-8.84%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.70
-0.24
-12.46%
HK:1093
CSPC Pharmaceutical Group
8.36
2.40
40.27%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.03
-8.57%
HK:0239
Pak Fah Yeow International Limited
2.50
0.39
18.48%
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Sets AGM to Approve Dividend and Share Issuance Mandate
Apr 27, 2026
Tong Ren Tang Technologies has convened its 2025 annual general meeting for 12 June 2026 in Beijing, where shareholders will review the audited 2025 financial statements and the board’s annual report. The company will also seek approval for ...
Tong Ren Tang Technologies Updates Final Dividend and Tax Details for 2025
Apr 27, 2026
Tong Ren Tang Technologies Co. Ltd. has announced an updated final cash dividend for the financial year ended 31 December 2025, declaring RMB 0.18 per share, subject to shareholder approval on 12 June 2026. The timetable has been revised, with the...
Tong Ren Tang Technologies Posts RMB1.81 Billion Q1 2026 Revenue on Preliminary Basis
Apr 27, 2026
Tong Ren Tang Technologies Co. Ltd. reported that, under PRC Accounting Standards, its group generated unaudited operating revenue of about RMB1,813.58 million and operating costs of about RMB1,109.42 million for the three months ended 31 March 20...
Tong Ren Tang Technologies to Update Articles for Hybrid Meetings and E-Voting
Apr 27, 2026
Tong Ren Tang Technologies Co. Ltd. plans to amend its Articles of Association to align with the Hong Kong Stock Exchange’s expanded paperless listing regime, ensuring its constitutional documents support hybrid general meetings and electron...
Tong Ren Tang Wins Macao Approval for New Traditional Chinese Medicine
Apr 20, 2026
Tong Ren Tang Technologies said its Macau subsidiary has received a Certificate of Registration of Proprietary Chinese Medicine from the Macao government’s Pharmaceutical Administration Bureau for its product Jin Chai Shi Hu San, enabling th...
Tong Ren Tang Technologies Proposes Final 2025 Dividend and Outlines Tax Treatment
Mar 27, 2026
Tong Ren Tang Technologies Co. Ltd. has announced a proposed final ordinary cash dividend of RMB 0.18 per share for the financial year ended 31 December 2025, with payment scheduled for 11 August 2026, subject to shareholder approval. Key timetabl...
Tong Ren Tang Technologies Profit Falls in 2025 as It Wraps Up 14th Five-Year Plan
Mar 27, 2026
Tong Ren Tang Technologies reported 2025 revenue of RMB6.48 billion, down 10.69% year-on-year, with net profit falling 25.51% to RMB660.63 million and earnings per share dropping to RMB0.31, while maintaining a stable dividend per share of RMB0.18...
Tong Ren Tang Subsidiary Posts Lower 2025 Profit as Revenue and Margins Decline
Mar 20, 2026
Tong Ren Tang Technologies reported that its subsidiary Beijing Tong Ren Tang Chinese Medicine Company Limited posted lower revenue and profit for 2025, with sales falling to HK$1.51 billion from HK$1.61 billion and profit attributable to owners d...
Tong Ren Tang Technologies Schedules Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Tong Ren Tang Technologies Co. Ltd. has scheduled a board meeting in Beijing on 27 March 2026 to review and approve the audited consolidated results for the year ended 31 December 2025. The board will also consider proposing a final dividend, pote...
Tong Ren Tang Technologies Renews Advertising Framework Deal With Controlling Shareholder
Feb 26, 2026
Tong Ren Tang Technologies has renewed its Advertising Agency Framework Agreement between its subsidiary Tong Ren Tang Century Advertising and ultimate controlling shareholder Tong Ren Tang Holdings, effective from 26 February 2026 to 31 December ...
Tong Ren Tang Technologies Overhauls Board with New Independent Director Appointment
Feb 6, 2026
Tong Ren Tang Technologies Co. Ltd. reported that shareholders approved, by a large majority vote at an extraordinary general meeting held in Beijing on 6 February 2026, the appointment of Mr. Siu, Paul Yu Hay as an independent non-executive direc...
Tong Ren Tang Technologies Details Board and Committee Structure
Feb 6, 2026
Tong Ren Tang Technologies Co. Ltd. has announced the current composition of its board of directors, led by Chairman Zhang Yi and General Manager Zhang Chun You, and comprising executive, non-executive, independent non-executive and an employee di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.